Health
Press Release: PHARMAC opens consultation to address New Zealand’s biggest health issue1 – PRWire
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal2 which could see up to 50,000 New Zealanders with type 2 diabetes and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal2 which could see up to 50,000 New Zealanders with type 2 diabetes and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but also reduces the risk of dying from heart complications.3,4
Under the new proposal, from 1December 2020, Jardiance (empagliflozin) would become the first and only oral diabetes medicine on New Zealands Pharmaceutical Schedule2 proven to deliver…
-
General14 hours agoWA government rolls out suite of housing assistance ahead of state budget
-
Business16 hours agoLeading brokers name 3 ASX shares to buy today 16 June 2025
-
Business20 hours agoHow many Magnificent 7 stocks should I own?
-
Noosa News15 hours agoPolice investigate fire at Borrodell Estate winery restaurant near Orange